Endocrinology, Vol 128, 13-20, Copyright © 1991 by Endocrine Society

ARTICLES

Epidermal growth factor induces the functional expression of dopamine receptors in the GH3 cell line

C Missale, L Castelletti, F Boroni, M Memo and P Spano
Institute of Pharmacology and Experimental Therapeutics, School of Medicine, University of Brescia, Italy.

GH3 cells are a clonal strain from a rat pituitary tumor that synthesizes and secretes both PRL and GH. The peculiarity of these cells is that they do not express receptors for dopamine; thus the hormone release is insensitive to the inhibitory effect of dopamine and D2 receptor agonists. Exposure of GH3 cells to epidermal growth factor for 4 consecutive days markedly altered the cell morphology, from a spherical appearance to an elongated flattened shape, and increased the cell size. These morphological changes were accompanied by the functional expression of D2 dopamine receptors as shown by the presence of a specific, saturable, and stereoselective high affinity binding for [3H]spiroperidol in epidermal growth factor-treated cells and by the fact that the selective D2 agonist quinpirole recovered the property to inhibit PRL secretion in the cell cultures exposed to the neurotrophic factor. The effect of EGF on the functional expression of D2 receptors was dose dependent (EC50 = 8 pM) and reversible. These data suggest that EGF elicits major effects on the expression of specific genes leading to the differentiation of GH3 cells into lactotroph-like cells endowed with dopamine D2 receptors.

This article has been cited by other articles:

				D. Ferone, M. Arvigo, C. Semino, P. Jaquet, A. Saveanu, J. E. Taylor, J.-P. Moreau, M. D. Culler, M. Albertelli, F. Minuto, et al. Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation Am J Physiol Endocrinol Metab, December 1, 2005; 289(6): E1044 - E1050. [Abstract] [Full Text] [PDF]

				R. B. McCall, K. J. Lookingland, P. J. Bedard, and R. M. Huff Sumanirole, a Highly Dopamine D2-Selective Receptor Agonist: In Vitro and in Vivo Pharmacological Characterization and Efficacy in Animal Models of Parkinson's Disease J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1248 - 1256. [Abstract] [Full Text] [PDF]

				A. Bahar, D. J. Simpson, S. J. Cutty, J. E. Bicknell, P. R. Hoban, S. Holley, M. Mourtada-Maarabouni, G. T. Williams, R. N. Clayton, and W. E. Farrell Isolation and Characterization of a Novel Pituitary Tumor Apoptosis Gene Mol. Endocrinol., July 1, 2004; 18(7): 1827 - 1839. [Abstract] [Full Text] [PDF]

				N. Ben-Jonathan and R. Hnasko Dopamine as a Prolactin (PRL) Inhibitor Endocr. Rev., December 1, 2001; 22(6): 724 - 763. [Abstract] [Full Text] [PDF]

				M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy Prolactin: Structure, Function, and Regulation of Secretion Physiol Rev, October 1, 2000; 80(4): 1523 - 1631. [Abstract] [Full Text] [PDF]

				H. Kanasaki, K. Fukunaga, K. Takahashi, K. Miyazaki, and E. Miyamoto Involvement of p38 Mitogen-Activated Protein Kinase Activation in Bromocriptine-Induced Apoptosis in Rat Pituitary GH3 Cells Biol Reprod, June 1, 2000; 62(6): 1486 - 1494. [Abstract] [Full Text]

				H. Kanasaki, K. Fukunaga, K. Takahashi, K. Miyazaki, and E. Miyamoto Mitogen-Activated Protein Kinase Activation by Stimulation with Thyrotropin-Releasing Hormone in Rat Pituitary GH3 Cells Biol Reprod, July 1, 1999; 61(1): 319 - 325. [Abstract] [Full Text]

				D. Ray and S. Melmed Pituitary Cytokine and Growth Factor Expression and Action Endocr. Rev., April 1, 1997; 18(2): 206 - 228. [Abstract] [Full Text]